Potassium Acetate
| Evidence Level: L4 | Predicted Indications: 10 |
Table of Contents
Potassium Acetate: From Potassium Deficiency to Renal Tubular Acidosis
One-Sentence Summary
Potassium acetate is a potassium and acetate salt, originally used to correct potassium deficiency. The TxGNN model predicts it may be useful for renal tubular acidosis, but no clinical trials and no publications were found for this drug in this indication, so the prediction rests on mechanistic reasoning alone.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Potassium deficiency disease |
| Predicted New Indication | Renal tubular acidosis |
| TxGNN Prediction Score | 99.90% |
| Evidence Level | L4 |
| Singapore Market Status | ✓ Marketed |
| Number of Registrations | 5 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available. Based on known information, potassium acetate supplies potassium, and its acetate component is metabolised to bicarbonate. Its use in potassium deficiency is established, and mechanistically it may be applicable to renal tubular acidosis.
In distal renal tubular acidosis, low potassium and metabolic acidosis often occur together. The potassium-repleting and alkalinising effects of potassium acetate therefore fit this picture. Alkali therapy, such as potassium citrate or bicarbonate, is already standard care. The link is therefore indirect and by analogy to those agents.
No studies of potassium acetate itself in this condition were found. The very high TxGNN score is a model prediction and does not replace clinical evidence.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Singapore Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| SIN05868P | DBL Potassium Acetate Concentrated Injection 2.45 g/5 ml | Injection | Not stated in the data compiled |
| SIN15411P | Aminoplasmal B.Braun 10% E Solution for Infusion | Infusion, solution | Not stated in the data compiled |
| SIN16734P | Nutriflex Omega Special B. Braun Emulsion for Infusion | Injection, emulsion | Not stated in the data compiled |
| SIN15469P | Nutriflex Omega Special Emulsion for Infusion | Injection, emulsion | Not stated in the data compiled |
| SIN15468P | Nutriflex Omega Plus Emulsion for Infusion | Injection, emulsion | Not stated in the data compiled |
All five registrations are injectable or infusion products. Oral forms were not identified.
Safety Considerations
- Drug Interactions: 40 interactions were identified in total. The main ones among those reviewed:
- Major: amiloride, benazepril, olmesartan, valsartan and azilsartan medoxomil. These potassium-sparing diuretics, ACE inhibitors and angiotensin receptor blockers can raise potassium levels, so hyperkalaemia is the main concern.
- Moderate: aliskiren.
- Minor: multiple insulin products (aspart, degludec, detemir, glargine, glulisine, lispro, human insulin and others).
Please refer to the package insert for warnings and contraindications, which were not available in the data compiled for this report.
Conclusion and Next Steps
Decision: Hold
Rationale: The mechanistic rationale is plausible, but it is indirect and no trials or literature support potassium acetate in renal tubular acidosis. The registered products are injectable and do not list an approved indication in the data compiled. Route compatibility with the new indication has not been assessed. Key interactions with potassium-raising drugs also need attention.
To proceed, the following is needed:
- Package insert warnings and contraindications from the HSA website
- Detailed mechanism of action data
- A targeted literature search on potassium and alkali therapy in renal tubular acidosis
- Assessment of route and formulation suitability, since the registered products are injectable
- A potassium and acid-base monitoring plan, including for patients on potassium-raising drugs
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.